Last edition
News about "Revuforj "
Syndax Announces Positive Revuforj Data in Acute Leukemias from Multiple Trials
Revuforj is the company's oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older.
Revuforj | 09/12/2024 | By Aishwarya | 328
Syndax Gets FDA Approval of Revuforj for Relapsed or Refractory Acute Leukemia
The safety evaluation of Revuforj was based on an FDA analysis of 135 patients with R/R acute leukemia with a KMT2A translocation who were treated with Revuforj.
Revuforj | 16/11/2024 | By Aishwarya | 306
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy